New York, New York (PRWEB) June 02, 2014
Thousands of vaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/)
continue to move forward in federal multidistrict litigations now underway in the U.S. District Court, Southern District of West Virginia, Bernstein Liebhard LLP reports. According to Orders dated May 29, 2014, the Court has issued revised Short Form and Amended Short Form Complaints in a number of the proceedings, including those involving American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326), C.R. Bard, Inc. (MDL No. 2187) and Ethicon, Inc. (MDL No. 2327). The revised documents reflect the dismissal of Ethicon LLC as a defendant, as well as the addition of four Neomedic defendants as required by the recent assignment of the Neomedic multidistrict litigation to the Southern District of West Virginia (MDL No. 2511)
“Our Firm represents numerous women with claims pending in the Southern District of West Virginia, all of whom were allegedly harmed by surgical mesh devices used to treat pelvic organ prolapse and stress urinary incontinence. We are pleased to see these proceedings moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free vaginal mesh lawsuit reviews to women who were allegedly harmed by transvaginal mesh products manufactured by American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Vaginal Mesh Lawsuits
Court documents indicate that more than 55,000 claims have been filed in the Southern District of West Virginia on behalf of women who allegedly suffered serious vaginal mesh complications, including mesh erosion, chronic pain, organ damage, and infections, following implantation of transvaginal mesh. All of these claims allege that the defendants’ pelvic mesh products were defectively designed and manufactured, and that doctors and patients were not provided with adequate warnings about their risks. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committees for several of these procedures, including American Medical Systems, Boston Scientific, C.R. Bard, and Ethicon.
Mr. Grand has also been appointed Co-Liaison Counsel in two multicounty litigations underway in New Jersey Superior Court for transvaginal mesh lawsuits involving products marketed by C.R. Bard and Ethicon. He was also a member of the Plaintiff’s trial team on the first Ethicon trial in that proceeding, which ended in March with a jury awarding $11 million in compensatory and punitive damages to a woman who was harmed by the Ethicon Gynecare Prolift device. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)
Alleged victims of serious vaginal mesh complications may be entitled to file their own transvaginal mesh lawsuit against the company that manufactured their implant. To learn more about the litigation involving transvaginal mesh, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP